Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Soligenix
Age
18–75
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Have a clinical diagnosis of plaque psoriasis (psoriasis vulgaris) of at least 6-months duration that involves the body (trunk and/or limbs) that is amenable to topical treatment and opaque coverage after application.
Have a static Investigator Global Assessment (IGA)/Psoriasis Area and Severity Index (PASI) of disease severity of mild or moderate on the body (trunk and/or limbs).
Have lesions involving 2-30% of the body (trunk and/or limbs). For subjects with scalp psoriasis included in the treatment area, the total treatment area on body and scalp must not exceed 30%.
You may not be if
Use of topical anti psoriatic therapy within one week prior to the beginning of the study and willing to not use other psoriasis treatments for 4 weeks following completion of the treatment portion of the study.
Received systemic biologic therapy to treat psoriasis within 12 weeks prior to the beginning of the study.
Received systemic psoriasis therapy within 4 weeks prior to the beginning of the study.
Received phototherapy (including laser) or photodynamic (light activated drug) therapy within 4 weeks prior to the beginning of the study.
